化痰通腑法治疗缺血性脑卒中急性期的随机对照研究

A randomized controlled trial on treating ischemic stroke during acute stage by the Huatan Tongfu therapy

目的:观察化痰通腑法治疗缺血性脑卒中急性期痰热腑实证的临床疗效,并通过超敏C-反应蛋白(Hs-CRP)的测定探讨其疗效机制。方法:纳入缺血性脑卒中急性期痰热腑实证的患者60例,其中治疗组30例,对照组30例。对照组给予常规治疗方法。治疗组在常规治疗的基础上加用化痰通腑类汤药星萎承气汤治疗。以上疗程均为10d。观察两组治疗前后中医证候评分、神经功能缺损程度评分的变化,并于患者入组时及入组第4、10天测定血清Hs-CRP,观察两组血清Hs-CRP的变化。结果:治疗组患者中医证候评分和神经功能缺损程度评分改善状况明显优于对照组(P<0.05),两组差异有统计学意义。治疗组Hs-CRP水平明显改善,优于对照组。结论:化痰通腑法治疗缺血性脑卒中急性期痰热腑实证有较好的临床疗效,推测作用机制可能与其能降低脑梗塞急性期血清Hs-CRP的水平,从而减轻脑缺血后炎性损伤有关。

Objective: To observe clinical efficacy of the Huatan Tongfu therapy on ischemic stroke of the Tanre Fushi type duringacute stage, and investigate mechanism through determining Hs-CRP. Methods: 60 patients were divided into two groups, 30 cases for each.The control group was treated by the conventional therapy; and the treatment group was given the Xinlou Chengqi decoction more, 10 daysas a course. TCM symptoms score and NIHSS in two groups were observed. At beginning, the 4th day and the 10th day, changes of serumHs-CRP in two groups were observed. Results: The improvement of TCM symptoms score and NIHSS in the treatment group was better(P<0.05); and the Hs-CRP level in the treatment group was improved more (P<0.05). Conclusion: The Huatan Tongfu therapy on ischemicstroke of the Tanre Fushi type during acute stage shows a good effect; and the active mechanism would be related to this therapy, whichdecrease serum Hs-CRP levels of patients with acute cerebral infarction, thus relieve inflammatory injury after cerebral ischemia.